Trials / Completed
CompletedNCT00038909
Study Evaluating ReFacto in Hemophilia A
Factor VIII Mutation Testing Program in Previously Untreated Patients (PUPs) With Hemophilia A Participating in ReFacto® Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 103 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To identify the causative mutations in previously untreated patients with hemophilia A enrolled in the ReFacto® clinical safety and efficacy study CTN 93-R833-0XX/C9741-28, using two established hemophilia mutation testing laboratories (one in Europe and one in North America).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BDDrFVII |
Timeline
- Start date
- 1994-09-01
- Primary completion
- 2001-05-01
- Completion
- 2001-05-01
- First posted
- 2002-06-07
- Last updated
- 2013-02-08
Source: ClinicalTrials.gov record NCT00038909. Inclusion in this directory is not an endorsement.